Diverse Sphingolipid Profiles in Rectal and Colon Cancer
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms241310867 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Adam R Markowski und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine and Gastroenterology, Polish Red Cross Memorial Municipal Hospital, 79 Henryk Sienkiewicz Street, 15-003 Bialystok, P…. Hauptthemen laut MEDLINE: Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical University of Bialystok.
Abstract (Originalsprache)
Colorectal cancer is a heterogenous group of neoplasms showing a variety of clinical and pathological features depending on their anatomical location. Sphingolipids are involved in the formation and progression of cancers, and their changes are an important part of the abnormalities observed during carcinogenesis. Because the course of rectal and colonic cancer differs, the aim of the study was to assess whether the sphingolipid profile is also different in tumors of these two regions. Using a combination of ultra-high-performance liquid chromatography combined with triple quadrupole mass spectrometry, differences in the amounts of cellular sphingolipids were found in colorectal cancer. Sphingosine content was higher in rectal cancer than in adjacent healthy tissue, while the content of two ceramides (C18:0-Cer and C20:0-Cer) was lower. In colon cancer, a higher content of sphingosine, sphinganine, sphingosine-1-phosphate, and two ceramides (C14:0-Cer and C24:0-Cer) was found compared to healthy tissue, but there was no decrease in the amount of any of the assessed sphingolipids. In rectal cancer, the content of sphinganine and three ceramides (C16:0-Cer, C22:0-Cer, C24:0-Cer), as well as the entire pool of ceramides, was significantly lower compared to colon cancer. The S1P/Cer ratio in rectal cancer (S1P/C18:1-Cer, S1P/C20:0-Cer, S1P/C22:0-Cer, S1P/C24:1-Cer) and in colon cancer (S1P/C18:0-Cer, S1P/C18:1-Cer, S1P/C20:0-Cer) was higher than in adjacent healthy tissue and did not differ between the two sites (rectal cancer vs. colonic cancer). It seems that the development of colorectal cancer is accompanied by complex changes in the metabolism of sphingolipids, causing not only qualitative shifts in the ceramide pool of cancer tissue but also quantitative disturbances, depending on the location of the primary tumor.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine and Gastroenterology, Polish Red Cross Memorial Municipal Hospital, 79 Henryk Sienkiewicz Street, 15-003 Bialystok, Poland.
- Department of Hygiene, Epidemiology and Metabolic Disorders, Medical University of Bialystok, 2C Adam Mickiewicz Street, 15-222 Bialystok, Poland.
- Department of Medical Biology, Medical University of Bialystok, 2C Adam Mickiewicz Street, 15-222 Bialystok, Poland.
ORCID-Profile: Adam R Markowski, Agnieszka U Błachnio-Zabielska, Piotr Zabielski
Förderung
- Medical University of Bialystok
Zitieren
APA
Markowski, A. R., Błachnio-Zabielska, A. U., Pogodzińska, K., Markowska, A. J., & Zabielski, P. (2023). Diverse Sphingolipid Profiles in Rectal and Colon Cancer. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms241310867
Vancouver
Markowski AR, Błachnio-Zabielska AU, Pogodzińska K, Markowska AJ, Zabielski P. Diverse Sphingolipid Profiles in Rectal and Colon Cancer. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms241310867
BibTeX
@article{Markowski2023,
author = {Markowski, Adam R and Błachnio-Zabielska, Agnieszka U and Pogodzińska, Karolina and Markowska, Anna J and Zabielski, Piotr},
title = {Diverse Sphingolipid Profiles in Rectal and Colon Cancer},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms241310867}
}
EUVIMED